---
layout: default
title: Ramucirumab
parent: 僅模型預測 (L5)
nav_order: 293
evidence_level: L5
indication_count: 10
---

# Ramucirumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ramucirumab: From VEGFR2-Driven Antiangiogenic Therapy to Uterine Ligament Adenocarcinoma

## One-Sentence Summary

> Ramucirumab is an anti-VEGFR2 monoclonal antibody; the original approved indication was not documented in the current evidence pack.
> The TxGNN model predicts it may be effective for **uterine ligament adenocarcinoma**,
> but this direction is currently supported by **0 clinical trials** and **0 publications** — prediction-only evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in evidence pack |
| Predicted New Indication | Uterine ligament adenocarcinoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on the rationale text accompanying the TxGNN prediction, ramucirumab is described as an anti-VEGFR2 monoclonal antibody that inhibits tumour angiogenesis — a mechanism with theoretical antitumour potential across highly vascularised solid tumours, including gynecological malignancies. However, the drug's original approved indication and detailed clinical MOA documentation were not provided in this evidence pack.

The predicted indication, uterine ligament adenocarcinoma, is an extremely rare histological subtype of gynecological cancer. The stated mechanistic rationale for pursuing this indication is that VEGF-driven angiogenesis is a shared feature across many gynecological malignancies, making VEGFR2 blockade a biologically plausible strategy. That said, the rationale itself explicitly notes there is **no clinical trial or literature evidence directly supporting this specific tumour subtype** — the connection is a generalized extrapolation from anti-angiogenic pharmacology rather than a validated, subtype-specific mechanistic finding.

All ten ranked predictions in this evidence pack (ranks 1–10) follow the same pattern: rare uterine/cervical adenocarcinoma subtypes, high TxGNN scores (>99.9%), but zero supporting trials or publications. This suggests the prediction signal is coming from network-level similarity among rare gynecological tumour nodes in the knowledge graph, rather than from disease-specific pharmacological evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Norway Market Information

Ramucirumab is currently **not marketed** in Norway, with **0 registered authorizations**. No license records are available in this evidence pack.

---

## Cytotoxicity

Based on the available rationale data, ramucirumab is classified as a **targeted antineoplastic agent (anti-VEGFR2 monoclonal antibody)**, distinct from conventional cytotoxic chemotherapy.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-VEGFR2 monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All ten predicted indications are extremely rare gynecological adenocarcinoma subtypes supported only by TxGNN model scores (Evidence Level L5), with zero clinical trials or literature evidence. Combined with the drug's non-marketed status in Norway (0 authorizations) and blocking-level data gaps in the safety label, there is currently insufficient basis to advance any of these candidates beyond hypothesis generation.

**To proceed, the following is needed:**
- TFDA/manufacturer package insert (warnings, contraindications) — flagged as a Blocking data gap
- Detailed mechanism of action (MOA) and drug classification data from DrugBank — flagged as a High-severity data gap
- Documentation of the drug's original approved indication(s) and Norway licensing history
- Preclinical or case-level evidence specifically linking VEGFR2 inhibition to uterine ligament/cervical adenocarcinoma subtypes before considering progression to S1 evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

